Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market

This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed im...

Повний опис

Збережено в:
Бібліографічні деталі
Автор: Philipp, Marc P.
Формат: Online
Мова:Англійська
Опубліковано: Nomos Verlagsgesellschaft mbH & Co. KG 2021
Предмети:
Онлайн доступ:29431
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!
_version_ 1869522012905406464
author Philipp, Marc P.
author_browse Philipp, Marc P.
author_facet Philipp, Marc P.
author_sort Philipp, Marc P.
collection Directory of Open Access Books
description This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany.
format Online
id doab-20.500.12854ir-50417
institution Directory of Open Access Books
language eng
publishDate 2021
publishDateRange 2021
publishDateSort 2021
publisher Nomos Verlagsgesellschaft mbH & Co. KG
publisherStr Nomos Verlagsgesellschaft mbH & Co. KG
record_format ojs
spelling doab-20.500.12854ir-504172023-12-20T16:24:33Z Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market Philipp, Marc P. K1-7720 Wettbewerbsrecht Handels- und Wirtschaftsrecht Kartellrecht bic Book Industry Communication::L Law This book discusses the implications of the 2009 EU Commission’s Pharmaceutical Sector Inquiry on originator’s opportunities to apply Intellectual Property related measures in defending against generic competition. It argues that on the one hand recent developments in EU competition law do indeed impose potential limitations on an originator’s ability to block or delay generic market entry. On the other hand, the book calls for a differentiated assessment of the rather broad allegations made by the sector inquiry. The book thereby presents and thoroughly analyzes six key issues identified by the EU Commission in the inquiry’s final report: Blocking/defensive patenting, patent thickets, patent-related disputes and litigation, follow-on innovation, authorized generic entries and patent settlement agreements as well as interventions into generic marketing authorization. The analysis aims at reducing legal uncertainty by providing a clearer picture of legal boundaries between legitimate and problematic conduct under Arts. 101 and 102 TFEU. The book also puts the sector inquiry’s findings into a forward-looking perspective by highlighting industry trends with the potential to transform traditional originator and generic business models. The author studied economics and law, has gained substantial expertise about strategy development as a consultant to the pharmaceutical industry and currently leads strategic research management at a large life sciences public research organization in Germany. 2021-02-11T16:26:17Z 2021-02-11T16:26:17Z 2018-11-05 12:58:39 2011 book 29431 9783845231037 https://directory.doabooks.org/handle/20.500.12854/50417 eng Munich Intellectual Property Law Center – MIPLC image/png Attribution 4.0 International https://www.nomos-elibrary.de/10.5771/9783845231037 Nomos Verlagsgesellschaft mbH & Co. KG http://dx.doi.org/10.5771/9783845231037 http://dx.doi.org/10.5771/9783845231037 20c8b06d-3b2b-4af2-acda-fbcfdfea5744 9783845231037 92 open access
spellingShingle K1-7720
Wettbewerbsrecht
Handels- und Wirtschaftsrecht
Kartellrecht
bic Book Industry Communication::L Law
Philipp, Marc P.
Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title_full Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title_fullStr Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title_full_unstemmed Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title_short Intellectual Property Related Generic Defense Strategies in the European Pharmaceutical Market
title_sort intellectual property related generic defense strategies in the european pharmaceutical market
topic K1-7720
Wettbewerbsrecht
Handels- und Wirtschaftsrecht
Kartellrecht
bic Book Industry Communication::L Law
topic_facet K1-7720
Wettbewerbsrecht
Handels- und Wirtschaftsrecht
Kartellrecht
bic Book Industry Communication::L Law
url 29431
work_keys_str_mv AT philippmarcp intellectualpropertyrelatedgenericdefensestrategiesintheeuropeanpharmaceuticalmarket